KVUE Stock Price Today (September 2026) — Kenvue Inc. Analysis & Key Metrics 2026-09-08
Kenvue Inc. (KVUE) is trading at $18.39, down 1.87% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Consumer Defensive growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $19.50 (6.0% upside).
- Volatility remains elevated (15.29% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (3.00% YoY) alongside significant competitive pressures.
KVUE Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Kenvue Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $44.32B
P/E Ratio
Forward P/E: 15.21
Revenue Growth
Year over Year
Analyst Target
+6.0% upside potential
Key Investor Questions About KVUE
What investors need to know before buying
Based on current market data, KVUE presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 34.32)
- Fundamentals say: Caution warranted (high leverage concerns)
KVUE's growth trajectory depends on its ability to expand within the Household & Personal Products sector while managing margin pressures.
- Future growth will depend on performance in core Household & Personal Products operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for KVUE investors include debt exposure and competitive dynamics in the Household & Personal Products industry.
- $8.61B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Household & Personal Products.
52-Week Trading Range
Over the past year, KVUE stock traded between $14.02 and $20.82—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 15.29% annualized volatility and β=0.27, the stock exhibits low sensitivity to market moves—making KVUE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Kenvue's Brand Strength and Innovation Strategy Support Growth
KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.
Can Kimberly-Clark Turn its $40 Billion Kenvue Bet into $2.1 Billion in Savings?
Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
This Dividend King Just Offered a Buy-the-Dip Opportunity
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus
Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...
Kimberly Clark (KMB) Stock Looks Below Fair Value While Earnings Lag
Kimberly-Clark stock has declined 11.1% over the past year, yet both its earnings multiples and a Discounted Cash Flow (DCF) intrinsic value estimate currently point to a cheaper valuation than the market price suggests. With the share price near US$110, the key issue for investors is whether this apparent discount fairly reflects the company’s cash generation and risk profile. The 11.1% share price decline over 1 year signals that investors have been cautious on Kimberly-Clark despite a...
Estee Lauder Stock Jumped On A Bigger Margin Promise
The beauty group's repricing rests on a profit plan it controls, while the low end of its new sales guidance is no faster than the year just ended.
Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings
Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...
Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?
In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...
Explore More Analysis for KVUE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Kenvue Inc.
Kenvue Inc. (KVUE) is currently trading at $18.39. The RSI (14-day) is at 34.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $19.50 implies 6.0% upside from current levels. Volatility is low at 15.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Kenvue Inc. (KVUE): The trailing P/E ratio is 21.64, which is in line with broader market averages. The forward P/E is 15.21, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.58, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 3.35. Price-to-Sales is 2.29. Valuation should be compared to Household & Personal Products industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering KVUE, the consensus price target is $19.50. This represents a 6.0% upside from the current price of $18.39. The range spans from a low target of $18.00 to a high target of $23.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Kenvue Inc. (KVUE) pays a dividend with a current yield of approximately 4.57%. The annualized dividend rate is $0.83 per share. The payout ratio is 97.7%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was 2026-08-12T00:00:00.000Z.
Key risks for Kenvue Inc. (KVUE) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Household & Personal Products sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Kenvue Inc.'s (KVUE) current debt and financial health profile: Total debt stands at $8.61B. The debt-to-equity ratio is 81.62, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.00, indicating adequate short-term liquidity. The quick ratio is 0.61. The company holds $1.11B in cash and equivalents. Free cash flow is positive at $1.91B, providing a cushion for debt servicing and shareholder returns.